Alterity Therapeutics Limited (NASDAQ:ATHE) Short Interest Down 36.1% in October

Alterity Therapeutics Limited (NASDAQ:ATHE) was the recipient of a significant decline in short interest in the month of October. As of October 15th, there was short interest totalling 6,200 shares, a decline of 36.1% from the September 30th total of 9,700 shares. Currently, 0.1% of the company’s shares are short sold. Based on an average daily volume of 14,200 shares, the short-interest ratio is currently 0.4 days.

Alterity Therapeutics Price Performance

Shares of ATHE stock traded down $0.01 during mid-day trading on Monday, hitting $1.16. The stock had a trading volume of 4,900 shares, compared to its average volume of 46,644. Alterity Therapeutics has a 12-month low of $1.01 and a 12-month high of $5.41. The firm’s 50-day moving average is $1.31 and its two-hundred day moving average is $1.68.

Alterity Therapeutics Company Profile

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia. The company’s lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson’s disease.